Evaluation of Natural Bioactive-Derived Punicalagin Niosomes in Skin-Aging Processes Accelerated by Oxidant and Ultraviolet Radiation
Mohamad EA, Aly AA, Khalaf AA, Ahmed MI, Kamel RM, Abdelnaby SM, Abdelzaher YH, Sedrak MG, Mousa SA.
- DOI
- 10.2147/dddt.s316247
- Record issued
- 2026-08-05
- Engine
- 7.15.0
- Exported
- 2026-09-20
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/245ce65c-8e4a-4f57-a343-2b9b2822d30d is authoritative.
How this rating was calculated
- IntegrityIntegrity concern ×5−2.5★
- ClaimsUnsupported claim (uncorroborated)−0.5★
- ClaimsOverstated claim−0.5★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- ReportingStudy design not met−0.5★
- ReportingKey resources not met−0.5★
- ReportingData & code availability not met−0.5★
- ReportingStatistical analysis partially met−0.25★
- ReportingReporting transparency partially met−0.25★
- CitationsRetracted reference cited−0.25★
- CitationsUnresolved reference−0.25★
- Statistics were not checked: no recomputable values were found in this text — no test statistic reported with its degrees of freedom, no effect estimate printed with both a 95% CI and a p-value, and no percentage printed with both its count and its denominator.
- No data or code availability links were detected to verify.
- 01Conclusion not supported by the paper’s own evidence
Punicalagin increased human TERT concentration in skin cells.
telomere shortening occurred significantly in both H2O2/HFB4 and cR samples by 64.20% and 14.22%, respectively, while punicalagin treated samples showed telomere shortening in s.R and s + H2O2 samples by only 31.19% and 6.5%, respectively
Resultsreviewer’s wording - 02Efficacy rests on an unvalidated surrogate endpoint
The efficacy claim rests on in vitro cell-based biomarkers (gene expression changes in MMP3, Col1A1, Timp3, TERT concentration, cell cycle arrest, and collagen level). The paper does not demonstrate target engagement at the tested dose (no PK/PD or dose–exposure relationship for the cellular effect) and does not cite validated evidence linking these surrogates to a clinical outcome in skin aging.
“Punicalagin succeeded in reducing the growth arrest of HFB4 cells, activated production of the Col1A1 and Timp3 genes, maintained collagen level, and lowered MMP3. Punicalagin increased human TERT concentration in skin cells.”
- 03Treatment effect not shown to be clinically meaningful
The reported effect sizes (e.g., percentage telomere shortening: 64.20% vs 31.19% for H2O2, 14.22% vs 6.5% for UV) are presented without any anchor to a clinically or biologically meaningful threshold. No minimal clinically important difference or reference to physiological relevance is provided.
“telomere shortening occurred significantly in both H2O2/HFB4 and cR samples by 64.20% and 14.22%, respectively, while punicalagin treated samples showed telomere shortening in s.R and s+H2O2 samples by only 31.19% and 6.5%”
- 04Study design lacks key rigor safeguards
The study design lacks essential rigor elements: no randomization, blinding, power analysis, proper replication, or outlier handling. Only basic controls are present.
- 05Key resources not identified
Key resources are poorly identified: cell line authentication and mycoplasma testing are absent, and most reagents lack catalog numbers. Only statistical software is adequately identified.
“Cell line HFB4 (Human fibroblast cells) was provided by the Tissue Culture Department, Vaccines & Sera (VACSERA), Egypt”
Methods - 06Data and code not shared
No data availability statement, data deposit, accession numbers, or code sharing are provided.
6 further findings of this severity or below — every one is in the sections below, filed under its error type.
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
The paper presents a clear rationale for using punicalagin-loaded niosomes as an anti-aging agent, but the study design lacks essential rigor elements (no randomization, blinding, power analysis, replicate distinction) and statistical reporting is incomplete. Key resources are poorly identified, data are not publicly available, and internal contradictions in the reported niosome sizes and TERT assay results undermine the conclusions.
This evaluation synthesizes three independent reviewer runs. The paper is an in vitro cell line study; biological variables and ethical approvals were deemed not applicable. The statistics verification component checked 0 tests, so no mathematical verification was performed. The citation check identified one retracted and one potentially fabricated reference.
Numerical inconsistencies
1 finding · worst mediumValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
- highinternal contradictionIn the TERT assay, untreated cells exposed to UV (cR) show 14.22% telomere shortening, while punicalagin-treated UV-exposed cells (s.R) show 31.19% shortening, which is more than double. This contradicts the claim that punicalagin protects against telomere shortening.
telomere shortening occurred significantly in both H2O2/HFB4 and cR samples by 64.20% and 14.22%, respectively, while punicalagin treated samples showed telomere shortening in s.R and s + H2O2 samples by only 31.19% and 6.5%, respectively
Resultsreviewer’s wording - mediuminternal contradictionThe reported size ranges of free and loaded niosomes differ between the Results and Discussion sections, raising a consistency concern.
Results: 'free ones (135–200 nm) and those loaded with punicalagin (185–335 nm)'. Discussion: 'The sizes ranged from 180 nm to 220 nm for the free niosomes, which is smaller than those loaded with niosomes (218–437 nm).'
Discussionreviewer’s wording - mediuminternal contradictionThe size of free niosomes is reported as 135-200 nm in the Results but as 180-220 nm in the Discussion, a clear numerical discrepancy.
Results: 'free ones (135–200 nm)'; Discussion: 'The sizes ranged from 180 nm to 220 nm for the free niosomes'
Discussionreviewer’s wording
Overstated conclusions
5 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Conclusions not supported by the paper’s own evidenceAssessed
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
- Conclusions overstated beyond the evidenceAssessed
- Conclusions only partially backed by the presented evidenceAssessed
8 major claims checked against the paper's own evidence: 2 not fully backed by the presented evidence (unsupported or overstated).
- unsupportedReviewer 1Punicalagin increased human TERT concentration in skin cells.The presented data show that punicalagin-treated UV-exposed cells (s.R) have higher telomere shortening (31.19%) than UV-only cells (cR, 14.22%), which contradicts the claim of increased TERT concentration. The data for s.R does not support protection.Evidence: Figure 8 and reported percentages.
telomere shortening occurred significantly in both H2O2/HFB4 and cR samples by 64.20% and 14.22%, respectively, while punicalagin treated samples showed telomere shortening in s.R and s + H2O2 samples by only 31.19% and 6.5%, respectively
Resultsreviewer’s wording - overstatedReviewers 1, 2Punicalagin is promising as a natural antioxidant to protect human skin from aging.The in vitro evidence supports antioxidant and anti-aging effects at the cellular level, but the claim implies clinical applicability without in vivo data, which is overstated.Evidence: All in vitro results.
“Punicalagin is promising as a natural antioxidant to protect human skin from aging.”
Discussion - partialReviewer 3Punicalagin is a promising natural antioxidant to protect human skin from aging.The in vitro data support the claim, but the claim is extrapolated to human skin without in vivo evidence; the paper acknowledges the need for further studies.Evidence: The in vitro results show protective effects, but the paper itself notes the need for in vivo studies.
“Because of complexity of skin aging, future studies are required to use human skin and in vivo swine skin model of UV-mediated skin damage and aging to define the efficacy of punicalagin niosomes in skin aging.”
Discussion - supportedReviewer 1Punicalagin succeeded in reducing the growth arrest of HFB4 cells.The cell cycle data show that punicalagin treatment reduces the percentage of cells arrested in G2/M compared to H2O2 or UV alone, supporting the claim.Evidence: Figure 6 shows cell cycle arrest percentages.
The cell percentage arrested in the G2/M phase increased in the case of cR and H2O2/HFB4 samples; however, the percentage of cells arrested in the G0/G1 phase diminished in the case of H2O2/HFB4 sample. The samples (s + H2O2 and s.R) that were pretreated with punicalagin showed an effect that opposed the effect resulting from H2O2 and UV radiation.
Resultsreviewer’s wording - supportedReviewer 1Punicalagin activated production of the Col1A1 and Timp3 genes, maintained collagen level, and lowered MMP3.RT-PCR results show increased Col1A1 and Timp3 expression and decreased MMP3 expression in punicalagin-treated groups compared to H2O2/UV groups.Evidence: Figure 7 shows fold change in gene expression.
MMP3 expression increased in cR and H2O2/HFB4 samples, and the expression of Col1A1 and Timp3 decreased in those two samples. The s + H2O2 and s.R samples showed an effect that opposed that resulted from H2O2 and UV radiation.
Resultsreviewer’s wording - supportedReviewers 2, 3Punicalagin reduces growth arrest of HFB4 cells caused by H2O2 and UV radiation.The cell cycle data (Figure 6) show that punicalagin treatment reduces the percentage of cells arrested in G2/M phase compared to H2O2 or UV alone, supporting this claim.Evidence: Figure 6 shows lower G2/M arrest in s+R and s+H2O2 samples versus cR and H2O2/HFB4.
The samples (s + H2O2 and s.R) that were pretreated with punicalagin showed an effect that opposed the effect resulting from H2O2 and UV radiation.
Resultsreviewer’s wording - supportedReviewers 2, 3Punicalagin activates production of Col1A1 and Timp3 genes and lowers MMP3.RT-PCR data (Figure 7) show increased Col1A1 and Timp3 expression and decreased MMP3 in punicalagin-treated groups compared to stressed controls.Evidence: Figure 7 shows fold changes for these genes.
The s + H2O2 and s.R samples showed an effect that opposed that resulted from H2O2 and UV radiation.
Resultsreviewer’s wording - supportedReviewers 2, 3Punicalagin increases human TERT concentration in skin cells.The TERT assay (Figure 8) shows that punicalagin-treated samples have less telomere shortening (higher TERT activity) compared to stressed samples, supporting the claim.Evidence: Figure 8 shows that punicalagin-treated samples have lower telomere shortening percentages (31.19% and 6.5%) compared to H2O2/HFB4 (64.20%) and cR (14.22%).
Punicalagin treated samples showed telomere shortening in s.R and s + H2O2 samples by only 31.19% and 6.5%, respectively, and cells were protected from telomere shortening-mediated by oxidative stress.
Resultsreviewer’s wording
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe efficacy claim rests on in vitro cell-based biomarkers (gene expression changes in MMP3, Col1A1, Timp3, TERT concentration, cell cycle arrest, and collagen level). The paper does not demonstrate target engagement at the tested dose (no PK/PD or dose–exposure relationship for the cellular effect) and does not cite validated evidence linking these surrogates to a clinical outcome in skin aging.
“Punicalagin succeeded in reducing the growth arrest of HFB4 cells, activated production of the Col1A1 and Timp3 genes, maintained collagen level, and lowered MMP3. Punicalagin increased human TERT concentration in skin cells.”
- INADEQUATEEffect sizeThe reported effect sizes (e.g., percentage telomere shortening: 64.20% vs 31.19% for H2O2, 14.22% vs 6.5% for UV) are presented without any anchor to a clinically or biologically meaningful threshold. No minimal clinically important difference or reference to physiological relevance is provided.
“telomere shortening occurred significantly in both H2O2/HFB4 and cR samples by 64.20% and 14.22%, respectively, while punicalagin treated samples showed telomere shortening in s.R and s+H2O2 samples by only 31.19% and 6.5%”
Data authenticity concerns
1 finding · worst mediumAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
- Methods and results do not matchAssessed
5 integrity concerns flagged (1 high).
- mediummethod result mismatchThe paper reports 'telomere shortening' based on the TERT ELISA assay, which measures telomerase enzyme concentration, not telomere length. The claim that telomere shortening occurred is not directly supported by the assay performed.
Telomere shortening occurred significantly in both H2O2/HFB4 and cR samples by 64.20% and 14.22%, respectively, while punicalagin treated samples showed telomere shortening in s.R and s + H2O2 samples by only 31.19% and 6.5%
Resultsreviewer’s wording - lowmethod result mismatchThe ELISA kit for TERT is described as 'BioVision, Inc., Milpitas CA, USA' but TERT concentration is reported as a percentage of telomere shortening, which is not a standard readout for a TERT ELISA. The method may not match the reported result.
Methods: 'TERT (Human) ELISA kit from BioVision.' Results: 'Telomere shortening occurred significantly in both H2O2/HFB4 and cR samples by 64.20% and 14.22%, respectively.'
Methodsreviewer’s wording
Reporting gaps
5 findings · worst highRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
- Data and code not sharedAssessed
- Key resources not identifiedAssessed
- Statistical reporting gaps (tests, assumptions, effect sizes)Assessed
- Study design lacks key rigor safeguardsAssessed
- Reporting/transparency gapsAssessed
The introduction cites numerous studies on skin aging mechanisms, UV damage, ROS, and the antioxidant potential of pomegranate extracts. It establishes a clear premise that punicalagin, a polyphenol, can counteract oxidative stress and photoaging. However, limitations of prior research are not explicitly addressed, and the rationale is somewhat generic.
“In this study, we extracted punicalagin from pomegranate peel and then encapsulated it in niosomes to treat the HFB4 cell line as an anti-aging agent.”
“Because of complexity of skin aging, future studies are required to use human skin and in vivo swine skin model of UV-mediated skin damage and aging to define the efficacy of punicalagin niosomes in skin aging.”
“The natural antioxidants from plant secondary metabolites can protect human skin from photoaging.”
The paper describes an in vitro study with five groups (untreated, H2O2, UV, punicalagin+H2O2, punicalagin+UV) but does not mention randomization of cell cultures to groups, blinding of the investigator, or a priori sample size calculation. Distinction between biological and technical replicates is not made, and no outlier handling is reported. The only adequate element is the presence of appropriate controls (untreated cells, H2O2-only, UV-only).
The study uses HFB4 human fibroblast cells, a cell line. The biological variables criteria (sex, age, weight, housing, demographics) are not relevant for cell line work. The species/strain/source is reported (human fibroblast cell line from VACSERA), but authentication is not provided. With only one applicable criterion (species_strain_source) and it being reported_but_inadequate, the dimension is not_applicable per the scoring rule (<2 applicable).
“HFB4 (human dermal fibroblast) cell lines were preserved as a culture of monolayer in Dulbecco′s Modified Eagle′s Medium”
The paper includes a generic 'Compliance with Ethical Standards' statement but no named IRB or IACUC. Since the work involves only a commercially available cell line and no non-public subject-level data, ethics approval is genuinely not applicable.
“The study was conducted in accordance with the international guidelines.”
“Cell line HFB4 (Human fibroblast cells) was provided by the Tissue Culture Department, Vaccines & Sera (VACSERA), Egypt”
“The study was conducted in accordance with the international guidelines.”
The cell line HFB4 is identified by source but not authenticated (e.g., STR profiling). Mycoplasma testing is not reported. Many reagents (e.g., FBS, antibiotics) are listed with vendor but no catalog numbers. The investigational product (punicalagin) is identified by reference standard vendor but the extracted punicalagin is not fully characterized. Software SPSS v.15.0 is adequately identified. Of 4 applicable sub-criteria (cell_line_authentication, mycoplasma_testing, reagents_identified, software_tools_identified), only software_tools_identified is adequate.
“Methanol, ethanol, and Tween 80 were supplied from Sigma-Aldrich Co. (Schnelldorf, Germany).”
“Cell line HFB4 (Human fibroblast cells) was provided by the Tissue Culture Department, Vaccines & Sera (VACSERA), Egypt”
“Fetal bovine serum (FBS) was purchased from Invitrogen Corp. (Carlsbad, CA, USA). Penicillin-streptomycin, trypsin, EDTA, and Hank’s buffer were purchased from Gibco, New York, NY, USA.”
“Tween 80 were supplied from Sigma-Aldrich Co. (Schnelldorf, Germany).”
The paper states 'one-way ANOVA analysis' for group comparisons and uses SPSS v.15.0. However, no verification of ANOVA assumptions (normality, equal variance) is reported. Exact p-values are not provided; only 'p ≤ 0.05 was considered significant'. Effect sizes and confidence intervals are not reported. Data are presented as bar charts with error bars labeled as standard deviation, but individual data points are not shown. Of 4 applicable sub-criteria, 2 (tests_named, software_identified) are adequate.
“Significant variations between groups were estimated using one-way ANOVA analysis.”
“Significant variations between groups were estimated using one-way ANOVA analysis.”
“The error bars represent standard deviation.”
“Data were examined using SPSS v. 15.0. Significant variations between groups were estimated using one-way ANOVA analysis. p ≤ 0.05 was considered significant.”
“The error bars represent standard deviation.”
The paper does not include any statement about data availability, repository deposit, or code sharing. All four sub-criteria are not reported, resulting in a fail.
Methods for extraction, niosome preparation, and cell assays are described but lack details such as primer sequences for RT-PCR and exact number of replicates. No reporting guideline (ARRIVE, CONSORT) is referenced. All outcomes appear to be reported, and conclusions are proportional to the in vitro data. A conflicts of interest statement is present, but funding sources are not mentioned.
“The authors declare that they have no conflicts of interest for this work.”
“Powdered peels were macerated with 20% methanol for 7 days in a dark place to avoid degradation by the effect of light.”
“future studies are required to use human skin and in vivo swine skin model of UV-mediated skin damage and aging to define the efficacy of punicalagin niosomes in skin aging.”
“Because of complexity of skin aging, future studies are required to use human skin and in vivo swine skin model of UV-mediated skin damage and aging to define the efficacy of punicalagin niosomes in skin aging.”
Broken references and links
2 findings · worst highReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
- Cites retracted workRecomputed
- References not resolvable to a published paperRecomputed
Checked 48 references by DOI: 36 verified — 1 retracted, 1 DOI unresolved, 9 no DOI (shown, not verified), 1 lookup failed.
- RETRACTED10.2147/ijn.s70449Formulation, and evaluation of a topical niosomal gel containing a combination of benzoyl peroxide and tretinoin for antiacne activityReason: Retraction
- UNRESOLVED10.4103/pr.pr_36_17In vitro evaluation of antioxidant potential of isolated compounds and various extracts of peel of Punica granatum LCited DOI does not resolve to any Crossref record.
- NO DOISkin agingNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NOT CHECKED10.1111/j.1541-4337.2010.00131.xPomegranate and its many functional components as related to human health: a Review[crossref] rate_limited 429 https://api.crossref.org/works/10.1111%2Fj.1541-4337.2010.00131.x?mailto=editorial%40alpha1science.com: HTTP 429
- NO DOITargeted drug delivery: a ReviewNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOINiosomes as carrier in dermal drug deliveryNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIReview article niosomes: a non-ionic surfactant based vesicles as a carriers for drug deliveryNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIEvaluation of transdermal targeted niosomal drug delivery of terbinafine hydrochlorideNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOINiosomes and liposomes - vesicular approach towards transdermal drug deliveryNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOINiosomes: a novel approach in modern drug delivery systemsNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIFormulation and evaluation of niosomes containing punicalagin, from peels of punica granatumNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIEvaluation of antioxidant activity of leave extract of Bauhinia rufescens Lam. (Caesalpiniaceae)No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
Copyediting
1 finding · worst lowWording, consistency and formatting errors that need correcting before submission.
- Wording or formatting errors that need correctingAssessed
12 copyedit issues flagged (1 major): mostly typo, consistency, clarity.
- MAJORconsistencyResults vs. Discussion“Results: 'free ones (135–200 nm)'; Discussion: 'sizes ranged from 180 nm to 220 nm for the free niosomes'”→ Harmonize the size ranges for free niosomes to be consistent.Contradiction in reported values.
- MINORtypoMethods, Effect of H2O2 and Punicalagin on HFB4“punicalagin (0.27 Mm)”→ Change 'Mm' to 'mM' for consistency with other concentrations.Capitalization error for millimolar.
- MINORtypoAbstract, Methods“Methods In this study, punicalagin was extracted from pomegranate, and concentrations of total polyphenolics and flavonoids were determined, and antioxidant activities were measured.”→ Add a line break or period after 'Methods' for clarity.Missing punctuation or formatting.
- MINORclarityResults, TERT Assay“telomere shortening occurred significantly in both H2O2/HFB4 and cR samples by 64.20% and 14.22%”→ Clarify if these are percentages of the control or absolute shortening values.Unclear comparison basis.
- MINORconsistencyResults vs. Discussion“Results: 'free ones (135–200 nm) and those loaded with punicalagin (185–335 nm)'; Discussion: 'The sizes ranged from 180 nm to 220 nm for the free niosomes... (218–437 nm).'”→ Unify the size ranges; ensure that the Results and Discussion report the same values.This discrepancy could confuse readers about the actual particle sizes.
- MINORotherMethods, 'Effect of H2O2 and Punicalagin on HFB4'“cells treated with punicalagin (0.27 Mm)”→ Change 'Mm' to 'mM' (millimolar) for consistency with standard notation.Capital M is ambiguous; mM is the correct SI abbreviation for millimolar.
- MINORotherMethods, 'Effect of H2O2 and Punicalagin on HFB4'“cells treated with concentration (0.27Mm) of punicalagin + exposing to UV (s.R)”→ Correct to '0.27 mM' and add a space before 'mM'.Same unit issue as above.
- MINORtypoAbstract, Results“Punicalagin increased human TERT concentration in skin cells.”→ No issue; but note that 'telomerase' is misspelled as 'telomerase' in the Discussion? Actually, it's correct.This is fine; but the abbreviation 'TERT' is used correctly.
- MINORclarityMethods, 'Preparation of Methanol Extract'“dried in a solar oven with temperature ranging from 27°C to 30°C (according to climate temperature) for nearly 10 days.”→ Specify the solar oven model or provide a more precise drying protocol to improve reproducibility.The description is vague; a solar oven with variable temperature is not standard.
- MINORconsistencyMethods, Effect of H2O2 and Punicalagin on HFB4“punicalagin (0.27 Mm)”→ punicalagin (0.27 mM)Inconsistent capitalization of 'M' in millimolar unit.
- MINORtypoAbstract“Methods In this study”→ Methods: In this studyMissing colon after 'Methods'.
- MINORclarityResults, TERT Assay“Telomere shortening occurred significantly in both H2O2/HFB4 and cR samples by 64.20% and 14.22%, respectively”→ The TERT assay showed decreased telomerase activity in both H2O2/HFB4 and cR samples by 64.20% and 14.22%, respectivelyThe assay measures TERT concentration, not telomere length directly.
The published work has significant methodological and reporting gaps that a reader should weigh carefully. The internal contradictions in the niosome size data and the TERT assay results warrant a correction or independent re-analysis. The presence of a retracted citation is a serious integrity concern.
- 1.HIGHrigorAddress the internal contradiction in the TERT assay: the data show that punicalagin-treated UV-exposed cells (s.R) have 31.19% telomere shortening versus 14.22% for UV-only cells (cR), contradicting the claim that punicalagin protects against telomere shortening. Either provide a corrected analysis or remove the claim.This is a direct contradiction between the presented data and the stated conclusion, which undermines the core finding of the paper.
- 2.HIGHrigorRemove or replace the retracted reference: 'Formulation, and evaluation of a topical niosomal gel containing a combination of benzoyl peroxide and tretinoin for antiacne activity' (DOI 10.2147/ijn.s70449).Citing a retracted paper is a serious integrity violation; the authors must identify a valid replacement or remove the citation.
- 3.HIGHrigorVerify the reference not found in any registry: 'In vitro evaluation of antioxidant potential of isolated compounds and various extracts of peel of Punica granatum L.' (DOI 10.4103/pr.pr_36_17). Provide the correct citation or remove it.A reference that cannot be located in Crossref/OpenAlex may be fabricated; the authors must confirm its existence and correct the bibliographic details.
- 4.HIGHreportingAdd a data availability statement specifying where the raw data (e.g., cell viability, gene expression, flow cytometry) can be accessed, or state that they are available from the corresponding author upon reasonable request.Without any data availability statement, the reproducibility of the findings cannot be assessed.
- 5.HIGHrigorHarmonize the reported niosome size ranges: Results state 135-200 nm for free niosomes, while Discussion states 180-220 nm. Correct the discrepancy.This is an internal contradiction that could affect the interpretation of the formulation's properties.
- 6.HIGHreportingReport exact p-values and effect sizes with confidence intervals for all statistical comparisons, and specify the post-hoc test used after ANOVA.Threshold-only p-values and lack of effect sizes are insufficient for a reader to assess the strength of the evidence.
- 7.HIGHrigorProvide cell line authentication (e.g., STR profiling) and mycoplasma testing results, or explicitly state that these were not performed as a limitation.Without authentication and mycoplasma testing, the identity and quality of the cell line are uncertain, affecting reproducibility.
- 8.HIGHreportingTemper the claim that 'Punicalagin is promising as a natural antioxidant to protect human skin from aging' to reflect the in vitro nature of the evidence, and add a caution about the need for in vivo validation.The current wording implies clinical applicability, which is not supported by the data.
- 9.HIGHreportingDisclose funding sources and grant numbers, even if the study was unfunded, in a separate section.Funding transparency is a standard reporting requirement, and its absence is a gap.
- 10.MEDIUMreportingProvide the primer sequences for all RT-PCR genes (MMP3, Col1A1, Timp3, beta-actin) in the Methods section.Without primer sequences, the RT-PCR assay cannot be reproduced.
- 11.MEDIUMreportingState the number of biological replicates (independent experiments) for each cell assay and distinguish them from technical replicates.This is essential for assessing the statistical reliability of the results.
- 12.MEDIUMcopyeditCorrect the unit 'Mm' to 'mM' throughout the manuscript (Methods, 'Effect of H2O2 and Punicalagin on HFB4') and add a space before the unit.Inconsistent or incorrect unit notation is a readability issue that could cause confusion.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.